news
X-ray screening identifies compounds that block a major coronavirus enzyme
A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
List view / Grid view
Coronavirus
news
Engineered airway lining created to study how COVID-19 affects respiratory tracts
Researchers have made a respiratory model of COVID-19, made from patient-derived stem cells, to understand how the virus affects respiration and which could be used to test possible drugs.
news
Novel antibody could reduce SARS-CoV-2 transmission
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
news
Five SARS-CoV-2 antiviral candidates revealed in drug screening study
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
news
Novel DNA-based COVID-19 vaccines induce immune responses in mice
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
news
COVID-19 vaccine candidate stimulates neutralising antibody production in vivo
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
news
New database to track neurological symptoms of COVID-19
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
news
T-cell exhaustion may limit long-term immunity in COVID-19 patients
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
news
Severe symptoms of COVID-19 are caused by brain infection in mice, finds study
Researchers found that SARS-CoV-2 persists in the brain after it is cleared in the lungs and concluded the severest and longest lasting symptoms of COVID-19 may be caused by brain infection.